Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics


Spero Therapeutics, Inc. (SPRO)

Today's Latest Price: $17.28 USD

0.30 (1.77%)

Updated Dec 2 4:00pm

Add SPRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SPRO Stock Summary

  • SPRO's went public 3.08 years ago, making it older than merely 9.84% of listed US stocks we're tracking.
  • Of note is the ratio of Spero Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 9.08% of US stocks have a lower such ratio.
  • SPRO's price/sales ratio is 41.77; that's higher than the P/S ratio of 94.85% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Spero Therapeutics Inc are AFMD, CDTX, GRTS, VIR, and CBIO.
  • Visit SPRO's SEC page to see the company's official filings. To visit the company's web site, go to sperotherapeutics.com.

SPRO Stock Price Chart Interactive Chart >

Price chart for SPRO

SPRO Price/Volume Stats

Current price $17.28 52-week high $17.85
Prev. close $16.98 52-week low $5.25
Day low $16.78 Volume 198,900
Day high $17.85 Avg. volume 208,879
50-day MA $13.56 Dividend yield N/A
200-day MA $11.59 Market Cap 469.79M

Spero Therapeutics, Inc. (SPRO) Company Bio


Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SPRO Latest News Stream


Event/Time News Detail
Loading, please wait...

SPRO Latest Social Stream


Loading social stream, please wait...

View Full SPRO Social Stream

Latest SPRO News From Around the Web

Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Spero Therapeutics prices equity offering at $10/piece

Spero Therapeutics (SPRO) shares slide ~8% in premarket, after the company prices its previously announced public offering of 4.785M common shares and 3.215M of its non-voting Series D Convertible Preferred Stock, at $10 each, for gross proceeds of $80M.Offer price represents a discount of ~10% from last close of $11.12.Underwriters have an...

Seeking Alpha | September 11, 2020

Spero Therapeutics initiates equity offering

Spero Therapeutics (SPRO) has commenced an underwritten public offering of 8M common shares and shares of non-voting Series D Convertible Preferred Stock with each share of Series D Convertible Preferred Stock being convertible into 1,000 shares of common stock.Underwriters will have an option to purchase up to an additional 15%...

Seeking Alpha | September 9, 2020

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on July 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,000 shares of its common stock to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). The 2019...

Yahoo | July 31, 2020

Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Spero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on August 6, 2020 at 4:30 p.m. EDT to report its second quarter 2020 financial results and provide an update on its business and pipeline. To access the call, please dial (877) 705-6003 (domestic) or (201) 493-6725 (international) and refer to conference ID 13706063. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media section of the Company’s website at www.sperothera...

Yahoo | July 29, 2020

Read More 'SPRO' Stories Here

SPRO Price Returns

1-mo 22.12%
3-mo 92.86%
6-mo 38.91%
1-year 51.98%
3-year 40.72%
5-year N/A
YTD 79.72%
2019 56.34%
2018 -47.66%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8803 seconds.